A Study to Evaluate the Ability of TNFR:Fc to Decrease the Amount of IL-6 (Interleukin-6) and TNF-Alpha (Tumor Necrosis Factor) in HIV-Infected Patients - Related Studies

A Study to Evaluate the Ability of TNFR:Fc to Decrease the Amount of IL-6 (Interleukin-6) and TNF-Alpha (Tumor Necrosis Factor) in HIV-Infected Patients

This study has been completed.

Study NCT00001116. Last updated on June 23, 2005. Information provided by National Institute of Allergy and Infectious Diseases (NIAID)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		HIV Infections

2	Additional conditions recognized in this trial
		Acquired Immunodeficiency Syndrome
		Infection
		Necrosis

3	More general conditions related to this trial
		Immune System Diseases
		Immunologic Deficiency Syndromes
		Lentivirus Infections
		Pathologic Processes
		Retroviridae Infections
		RNA Virus Infections
		Sexually Transmitted Diseases
		Sexually Transmitted Diseases, Viral
		Slow Virus Diseases
		Virus Diseases

4	Additional drug interventions recognized in this trial
		TNFR-Fc fusion protein

5	More general drug interventions related to this trial
		Analgesics
		Analgesics, Non-Narcotic
		Anti-Inflammatory Agents
		Anti-Inflammatory Agents, Non-Steroidal
		Antirheumatic Agents
		Central Nervous System Agents
		Gastrointestinal Agents
		Immunologic Factors
		Immunosuppressive Agents
		Peripheral Nervous System Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Sensory System Agents
		Therapeutic Uses

6	Sponsors listed in this trial
		National Institute of Allergy and Infectious Diseases (NIAID)